Retrospective Cohort Study
Copyright ©The Author(s) 2023.
World J Gastroenterol. Aug 28, 2023; 29(32): 4883-4899
Published online Aug 28, 2023. doi: 10.3748/wjg.v29.i32.4883
Table 1 Clinicopathologic characteristics of the study patients
Clinical characteristics (n = 2203)
Value1
Age (yr)64.7 ± 12.2
Sex
    Male1264 (57.4)
    Female939 (42.6)
Body mass index (kg/m2)23.9 ± 3.3
ASA score
    1575 (26.1)
    21412 (64.1)
    3211 (9.6)
    45 (0.2)
Cancer location
    Cecum46 (2.1)
    Ascending colon386 (17.5)
    Hepatic flexure88 (4.0)
    Transverse colon115 (5.2)
    Splenic flexure18 (0.8)
    Descending colon79 (3.6)
    Sigmoid colon771 (35.0)
    Rectum700 (31.7)
Preoperative CEA (ng/mL)7.7 ± 42.3
Diverting stoma
    Ileostomy435 (19.7)
    Colostomy62 (2.8)
T stage
    018 (0.8)
    1275 (12.5)
    2383 (17.4)
    31282 (58.2)
    4245 (11.1)
N stage
    01286 (58.4)
    1639 (29.0)
    2278 (12.6)
Tumor size (cm)4.4 ± 2.4
    Lymphatic invasion597 (27.1)
    Vascular invasion469 (21.3)
    Perineural invasion934 (42.4)
    Harvested lymph nodes45.3 ± 21.2
    Metastatic lymph nodes1.4 ± 2.9
Adjuvant/Neoadjuvant therapy
    Colon
    Adjuvant therapy-stage II274 (51.4)
    Adjuvant therapy-stage III575 (90.0)
Rectum
    Neoadjuvant therapy200 (28.6)
    Operative first-Adjuvant therapy264 (52.8)